Johnson & Johnson reports second-quarter 2026 results on Wednesday, July 15, before the market opens. The framing on the day will be the round number: 2026 is the year J&J is supposed to cross $100 billion of annual revenue for the first time in its history.
The April guidance put estimated reported sales at $100.3–101.3 billion, midpoint $100.8 billion. The first quarter delivered $24.06 billion. That leaves $76.74 billion to find across three quarters — an average of $25.58 billion each.
J&J has never reported a $25 billion quarter. The largest in its history is $24.56 billion, in the December 2025 quarter. So the guidance does not require one good quarter; it requires three consecutive quarters, each larger than any quarter the company has ever had, starting on Wednesday.
What the run rate actually looks like
| Quarter | Reported sales |
|---|---|
| 2025 Q1 | $21.89B |
| 2025 Q2 | $23.74B |
| 2025 Q3 | $23.99B |
| 2025 Q4 | $24.56B |
| 2026 Q1 | $24.06B |
| Needed, average of next three | $25.58B |
Read down the column and the requirement is a step, not a continuation. The last four quarters have averaged $24.09 billion; the next three need to average 6.2% more than that.
Two things make it less improbable than the table suggests, and both are worth naming before Wednesday rather than after:
- Currency turned. J&J guided in April on a euro assumption of $1.17. The reported-sales line is the one currency moves; the company's own operational guidance — which strips translation — was $99.7–100.7 billion, a lower range than the reported one. If the dollar stayed weak through the June quarter, the reported figure gets help the operational figure does not.
- The comparison base rises through the year. $25.58 billion against 2025 Q2's $23.74 billion is 7.8% growth. Against 2025 Q4's $24.56 billion it is 4.2%. The requirement is front-loaded onto exactly the quarter being reported Wednesday.
So the single most informative number in the release is the June-quarter sales line, and the bar is roughly $25.6 billion if the year is going to land where April said it would without a guidance change.
The consensus is not measuring the same thing the company reports
The published consensus for Wednesday is $2.84 of EPS on $25.05 billion of revenue. That EPS figure is on J&J's adjusted line, and the gap between adjusted and GAAP at this company is large and structural, not occasional:
- 2025 Q2: GAAP $2.29, adjusted $2.77 — a 48-cent wedge.
- 2026 Q1: GAAP $2.14, with the adjusted line again well above it.
The wedge is mostly intangible-asset amortization, which runs over a billion dollars a quarter and does not stop, plus litigation and restructuring charges. Anyone subtracting $2.84 from a GAAP number Wednesday will manufacture a large miss out of nothing. The comparison that means something is adjusted-to-adjusted, and the number to hold it against is $2.77.
Note also the revenue consensus: $25.05 billion is below the $25.58 billion the April guidance implies for the average of the remaining quarters. The estimate feed and the company's own guidance are not telling the same story about this quarter, which is unusual enough to be the thing to check first.
What to watch on July 15
- The sales line against $25.6 billion. Below it and the $100 billion year needs the second half to make up the difference; the guidance range is only a billion dollars wide, so there is not much room.
- Whether the guidance range moves, and which one. J&J publishes reported sales, operational sales, adjusted EPS and adjusted operational EPS ranges separately. A raise on reported sales with the operational range untouched is currency; a raise on the operational line is the business.
- The STELARA drag on Innovative Medicine. Biosimilar erosion has been the single largest identifiable headwind to the segment's growth. The release quantifies it in basis points — that number is the cleanest read on how much of the erosion is behind them.
- MedTech's operational growth. It has been running several points below Innovative Medicine. If the $100 billion year happens, it happens in pharma, and MedTech's number tells you how much weight the rest of the company is carrying.
- Any new restructuring or separation charge. J&J is separating its Orthopaedics business and running a legacy Orthopaedics restructuring program. Both land in the GAAP-to-adjusted bridge, and both widen the wedge the consensus does not measure.
Quarterly sales history and GAAP diluted EPS are as Johnson & Johnson reported them for each period. The 2026 guidance ranges, the euro assumption and the prior-year adjusted EPS of $2.77 are from the company's own first-quarter 2026 disclosure of April 2026. The $76.74 billion remaining, the $25.58 billion three-quarter average, the 6.2% step against the trailing four-quarter average and the growth rates against prior quarters are our arithmetic on those disclosed figures, not company guidance. The $2.84 EPS and $25.05 billion revenue consensus, are press-reported from third-party estimate feeds this site does not store or verify; consensus for this company is set on the adjusted line, not the GAAP one. No price, valuation or rating figure appears above. These are expectations, not results.
